Children's Medical Center Corporation

Beth Israel Deaconess Medical Center, Inc.

Frances E Jensen

Alvaro Pascual-Leone

Paul A Rosenberg

Sanjay N Rakhade

Alexander Rotenberg

Joseph Volpe

Iain Glass

Pamela L Follett

Method and devices are provided for treating subjects with Transcranial Magnetic Stimulation (TMS). According to some approaches, the methods and devices are configured for the treatment of ongoing seizures. Other approaches relate to the use of TMS as an antiepileptogenic or for use in determining preferential placement of intracranial probes.

Transcranial magnetic stimulation (TMS) methods and apparatus

Inhibitors of NKCC1, such as bumetanide, when coadministered with inhibitors of GABA transaminase, such as vigabatrin, attenuate both the retinal toxicity and the intramyelinic edema.

Combination therapies: inhibitors of GABA transaminase and NKCC1

Patients are subject to a post-seizure treatment regime to separately inhibitor consecutive targets of an epileptogenic cascade comprising neurotransmitter receptor signaling, kinase/phosphatase activity, protein translation, and apoptosis or inflammation.

Treating post-seizure patients

Methods are disclosed for modulating brain damage mediated by non-NMDA ionotropic glutamate receptor antagonists, as topiramate, in conditions such as periventricular leukomalacia, cerebral palsy, mental retardation and neonatal stroke.

Growing community of inventors

Chestnut Hill, MA, United States of America

Frances E Jensen